and is also co-Founder and Senior Managing Director of Vida Ventures, a life science venture group with offices in Boston and Los Angeles.Īrie is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He serves as director of IconOVir Bio, Inc.
He currently serves as Chairman of Two River Group and UroGen Pharma, Kronos Bio, and Bellco Capital, and as co-Chairman of Breakthrough Properties LLC. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. Arie previously founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017.Īrie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. He is also the founding Chairman of Kronos Bio, a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics targeting dysregulated transcription. A visionary entrepreneur, Arie is the co-founder and Executive Chairman of Allogene Therapeutics, a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors.
0 kommentar(er)
